From the Journals

New PsA questionnaire fails to beat existing early screening methods

Publish date: April 12, 2018

 

FROM JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY


AbbVie supported this study with an educational grant. The study was supported by the National Institute for Health Research Leeds Biomedical Research Centre. Some of the authors reported potential conflicts of interest.

SOURCE: Coates L et al. J Eur Acad Dermatol Venereol. 2018 Mar 26. doi: 10.1111/jdv.14971.

Pages

Recommended Reading

Could guselkumab be a disease-modifying agent in plaque psoriasis?
Psoriasis Collection
VIDEO: PPACMAN aims to advance the combined rheum-derm clinic approach in the community
Psoriasis Collection
Do Psoriasis Patients Engage In Vigorous Physical Activity?
Psoriasis Collection
Xeljanz: FDA panel recommends ulcerative colitis indication
Psoriasis Collection
Study highlights need to investigate psoriasis treatment outcomes in skin of color patients
Psoriasis Collection
PASI responses with biologics similar among white, nonwhite individuals, study finds
Psoriasis Collection
FDA approves IL-23 antagonist for plaque psoriasis
Psoriasis Collection
FDA approves certolizumab label update for pregnancy, breastfeeding
Psoriasis Collection
Study using U.K. data quantifies infection risk associated with psoriasis
Psoriasis Collection
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
Psoriasis Collection

Related Articles

  • Latest News

    Dr. Jashin J. Wu

    Make a PEST of your psoriasis patients

    Author:
    Bruce Jancin
    Publish date: February 6, 2018

    KAUAI, HAWAII – Every psoriasis patient should complete the Psoriasis Epidemiology Screening Tool (PEST) for psoriatic arthritis annually.